Literature DB >> 2535348

Zinc in mononuclear leucocytes in alcoholics with liver cirrhosis or chronic pancreatitis and in patients with Crohn's disease before and after zinc supplementation.

S Bro1, M Stokholm, P J Jørgensen.   

Abstract

Mononuclear leucocyte zinc was determined together with serum zinc, albumin and serum alkaline phosphatase activity before and after zinc supplementation (2 x 50 mg of zinc-gluconate daily during 3 months) in patients with alcoholic liver cirrhosis (n = 10), alcoholic chronic pancreatitis (n = 10) and Crohn's disease (n = 10). Initial mononuclear leucocyte zinc concentrations did not differ between the patient groups and the reference group (n = 10), whereas initial serum zinc values were lower in the patients with alcoholic liver cirrhosis and Crohn's disease. This difference disappeared, however, when serum zinc concentrations were corrected for albumin levels, which were lower in all the patient groups. Higher initial activity of serum alkaline phosphatase was found in the alcoholic patients. In all the patient groups serum zinc concentrations increased significantly after zinc supplementation. Only in patients with Crohn's disease was there also an increase in serum alkaline phosphatase and albumin. Mononuclear leucocyte zinc did not respond to zinc supplementation in any of the patient groups. The results of our study indicate that mononuclear leucocyte zinc is not a sensitive indicator of marginal zinc deficiency.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535348

Source DB:  PubMed          Journal:  J Trace Elem Electrolytes Health Dis        ISSN: 0931-2838


  2 in total

Review 1.  Copper and zinc body levels in inflammation: an overview of the data obtained from animal and human studies.

Authors:  R Milanino; M Marrella; R Gasperini; M Pasqualicchio; G Velo
Journal:  Agents Actions       Date:  1993-07

Review 2.  Zinc and the liver: an active interaction.

Authors:  Ioannis Stamoulis; Grigorios Kouraklis; Stamatios Theocharis
Journal:  Dig Dis Sci       Date:  2007-04-06       Impact factor: 3.487

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.